SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Taus upcoming oncology milestones are driving attention, particularly the completed IMPACT pancreatic-cancer trial enrollment and expected data, alongside further REGAIN glioblastoma updates. Traders are broadly optimistic about the expanding pipeline, while some emphasize that larger datasets are still needed to validate the early results.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys quarterly results, particularly resilient parks performance and improving streaming profitability, have reinforced bullish sentiment and prompted analyst upgrades. Traders remain divided, with some seeing a turnaround while others point to the stocks long stretch of weak, range-bound performance.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is pulling back after a strong run as traders position ahead of earnings, with some wary of recent SaaS-sector weakness and the stocks valuation. Others remain bullish on growth and AI-driven commerce, while security concerns appear in some bearish posts but are not the dominant discussion.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned Q4 BLA submission for CAN-2409 in localized prostate cancer and upcoming SITC pipeline data. Bulls see the clinical and regulatory milestones as potential catalysts, while skeptics point to the steep decline, CEO share sales, limited transparency, possible dilution and uncertainty about filing timing; some also blame broader biotech weakness and thin trading.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias early third-quarter report and raised full-year revenue guidance are driving attention, with continued LUPKYNIS sales growth supporting the results. Traders are split between viewing the report as solid execution and frustration that the shares fell despite it, compounded by confusion over whether management held an earnings call.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys shares are drawing attention after a sharp post-earnings rally despite revenue and EPS misses; traders are focusing on premium subscriber growth, stronger gross margin, and an upbeat fourth-quarter profit outlook. The move has surprised some investors, who question why the stock rose on a mixed report, while bulls see the guidance and improving ad revenue as the more important signals.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is drawing attention amid a sharp pullback alongside other AI and semiconductor stocks, with traders citing stretched valuations, broad market pressure, and uncertainty ahead of earnings. The community is split between buyers treating the decline as an opportunity and bears warning that the stock remains overvalued and could fall further.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs large equity and warrant offering, alongside its Elisity acquisition, has put dilution and capital allocation at the center of the discussion as shares have sold off. Bulls see the financing and acquisitions as building a broader quantum platform, while critics question shareholder costs and execution; a Google quantum breakthrough has also lifted sector optimism, though traders disagree on whether that can overcome IONQ-specific concerns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could weaken in 2027 has sparked concerns about pricing and CorMedixs largest revenue driver, contributing to a sharp selloff. Traders are divided over the impact: some see a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMS reimbursement estimates as a reason the reaction may be excessive.

NEAR Protocol (NEAR) is a cryptocurrency launched in 2020. NEAR Protocol has a current supply of 1,310,395,414. The last known price of NEAR Protocol is 4.30157975 USD and is up 6.10 over the last 24 hours. It is currently trading on 688 active market(s) with $1,245,620,491.67 traded over the last 24 hours. More information can be found at https://near.org/.

Near

Traders are watching a governance vote that could make NEAR less inflationary, with some viewing the tokenomics change as a potential catalyst. Sentiment is split: dip-buyers are accumulating, while cautious traders point to Bitcoin-linked weakness and liquidation risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compared to Estimates, Rollins (ROL) Q3 Earnings: A Look at Key Metrics

The headline numbers for Rollins (ROL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ROL's Q3 Earnings Miss Estimates on Weak Demand & Higher Costs

Rollins' Q3 2026 earnings and revenues fall short of estimates as rising costs & weak residential demand pressure margins despite commercial & termite growth.

Rollins (ROL) Q3 Earnings and Revenues Miss Estimates

Rollins (ROL) delivered earnings and revenue surprises of -2.86% and -3.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

ROLLINS, INC. REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

ROLLINS, INC. REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS ROLLINS, INC. REPORTS THIRD QUARTER 2026 FINANCIAL RESULTSPR NewswireATLANTA, Oct. 21, 2026 ATLANTA, Oct. 21, 2026 /PRNewswire/ -- Rollins, Inc. (NYSE:ROL) ("Rollins" or the "Company"), a premier global consumer and commercial services...

ROLLINS, INC. INCREASES REGULAR QUARTERLY CASH DIVIDEND

ROLLINS, INC. INCREASES REGULAR QUARTERLY CASH DIVIDEND ROLLINS, INC. INCREASES REGULAR QUARTERLY CASH DIVIDENDPR NewswireATLANTA, Oct. 20, 2026 ATLANTA, Oct. 20, 2026 /PRNewswire/ -- Rollins, Inc. (NYSE: ROL), a premier global consumer and commercial services company, announced that the Board of...

Unlocking Q3 Potential of Rollins (ROL): Exploring Wall Street Estimates for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Rollins (ROL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.

Rollins Gears Up to Report Q3 Earnings: What's in the Cards?

ROL is set to report Q3 2026 earnings, with revenues expected to rise 9.6% while EPS remains flat amid higher buyout and integration costs.

Rollins (ROL) Reports Next Week: What to Know Ahead of the Release

Rollins (ROL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ROLLINS, INC. SCHEDULES DATE FOR RELEASE OF THIRD QUARTER 2026 FINANCIAL RESULTS

ROLLINS, INC. SCHEDULES DATE FOR RELEASE OF THIRD QUARTER 2026 FINANCIAL RESULTS ROLLINS, INC. SCHEDULES DATE FOR RELEASE OF THIRD QUARTER 2026 FINANCIAL RESULTSPR NewswireATLANTA, Oct. 7, 2026ATLANTA, Oct. 7, 2026 /PRNewswire/ -- Rollins, Inc. (NYSE: ROL), a premier global consumer and commercial...

Rollins, Inc. Announces Availability of Recorded Fireside Chat from J.P. Morgan Annual U.S. All Stars Conference

Rollins, Inc. Announces Availability of Recorded Fireside Chat from J.P. Morgan Annual U.S. All Stars Conference Rollins, Inc. Announces Availability of Recorded Fireside Chat from J.P. Morgan Annual U.S. All Stars ConferencePR NewswireATLANTA, Sept. 23, 2026 ATLANTA, Sept. 23, 2026 /PRNewswire...

Rollins, Inc. is an international services company, which engages in the provision of pest and termite control services. Its service offerings include Residential, Commercial, and Termite. The company was founded by John W. Rollins Jr. and O. Wayne Rollins Sr. on February 24, 1948 and is headquartered in Atlanta, GA.

Rollins, Inc.

Why Did BSX, LI, ROL Stocks Fall To 52-Week Lows On Friday? 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Boston Scientific shares fell to a 52-week low of $48.13 and lost 16% for the week after weaker expectations for its Watchman device business.&nbsp;</li><li>Li Auto came under pressure after reporting weaker profitability, prompting Barclays to cut its price target to $14 from $18.&nbsp;</li><li>Bernstein downgraded Rollins and cut its price target to $52 from $70, citing concerns that CFO Ken Krause’s departure could slow profitability improvements.&nbsp;</li></ul>Boston Scientific Corp. (BSX), Li Auto Inc. (LI), and Rollins Inc. (ROL) each dropped to new 52-week lows on Friday as investor sentiment toward premium-priced growth stocks took a hit.&nbsp;Concerns surrounding product growth, earnings prospects, and valuation levels weighed on the three companies. While&nbsp;<a href="https://stocktwits.com/symbol/LI">Li Auto</a> and&nbsp;<a href="https://stocktwits.com/symbol/ROL">Rollins</a> stocks declined over 3% each,&nbsp;<a href="https://stocktwits.com/symbol/BSX">Boston Scientific stock</a> ended Friday’s session over 1% lower.&nbsp;<h2 class="st-heading-2">BSX Faces&nbsp;Growth Questions</h2>Boston Scientific stock hit a 52-week low of $48.13, enduring a 16% weekly decline on weaker expectations for the company's Watchman heart-device franchise.&nbsp;Management's indication that U.S. Watchman revenue could remain weak through the next two quarters raised doubts about the pace of future expansion and prompted analysts to lower price targets.On Friday, both Wolfe Research and TD Cowen adjusted their views on the company. Wolfe Research downgraded Boston Scientific to ‘Peer Perform’ from ‘Outperform’.&nbsp;The firm revised its financial projections after incorporating management's updated outlook for the Watchman device business. Analysts now estimate organic revenue expansion of roughly 7% in 2027, a pace they believe supports a share valuation in the low-$50 range, close to where the stock currently trades.TD Cowen lowered its price target to $61 from $80 and maintained its Buy rating on Boston Scientific. However, on Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory.&nbsp;<h2 class="st-heading-2">LI Battles EV Industry Headwinds</h2>Li Auto came under pressure after its first-quarter earnings report on Thursday showed weaker profits. The Chinese EV maker also forecast lower Q2 deliveries of 95,000 to 100,000 vehicles, pointing to softer demand and intense competition in China's price-cutting EV market.&nbsp;Li Auto posted Q1 revenue of RMB23 billion ($3.3 billion), representing an 11% decline from last year. The company recorded a net loss of RMB2.3 billion for the quarter, a sharp reversal from the RMB646.6 million net profit it generated last year.Following the Q1 earnings report, Barclays lowered its price target on Li Auto to $14 from $18 while maintaining an ‘equal weight’ rating on the stock. The new price target implies nearly a 7% downside to the stock’s closing price on Friday.&nbsp;Retail sentiment around the stock turned to ‘bullish’ from ‘neutral’ territory the previous day.&nbsp;<h2 class="st-heading-2">ROL Confronts Valuation Reset</h2>Rollins reached a new yearly low of $46.85 despite reporting solid operating performance in April. Investors instead focused on valuation concerns, with some analysts arguing that the stock's premium pricing no longer aligns with its expected growth trajectory.&nbsp;The upcoming appointment of a new chief financial officer in mid-June added another variable for investors evaluating future performance.On Friday, Bernstein analyst Connor Cerniglia downgraded Rollins to ‘Market Perform’ from ‘Outperform’ and lowered his price target to $52 from $70, citing concerns that the CFO departure could complicate efforts to improve profitability in the years ahead.The analyst pointed to the departure of CFO Ken Krause, describing him as an important contributor to the company's efforts to enhance profitability and streamline operations.Retail sentiment around the stock changed to ‘bullish’ from ‘extremely bullish’ the previous day.&nbsp;So far this year, while BSX and ROL stocks have declined by over 49% and&nbsp; 20% respectively, LI stock has shed over 11%.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tmhc-stock-jumps-berkshire-acquisition-housing-bet/cZ0gaFFReu1">TMHC Stock Jumps Into Spotlight After Berkshire's Surprise $8.5B Housing Bet</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Employees adjust new energy vehicles at the workshop of Li Auto Changzhou Manufacturing Base on December 10, 2024 in Changzhou, Jiangsu Province of China. (Photo by Chen Wei/VCG via Getty Images)

Boston Scientific Corp. (BSX), Li Auto Inc. (LI), and Rollins Inc. (ROL) each dropped to new 52-week lows on Friday as investor sentiment toward premium-priced growth stocks took a hit.&nbsp;

Analyst downgrades, weak outlooks, and management changes added pressure. 


Boston Scientific Corp.

Li Auto Inc - ADR

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$34.66
Prev Close	$34.69
Open	$35.43
Dividend Yield	1.13%
50-Day Moving Average	$33.53
Beta	0.31
Avg. Volume	7.55M
PE Ratio	31.68

52-Week High	$66.14
52-Week Low	$29.29
Market Capitalization	$16.57B
EPS (Annual)	$1.09
Price to Book	11.92
Revenue Per Employee	$171,377.47

Feed

News

Sentiment

Earnings

Fundamentals

Info

ROL Fundamentals